Rang & Dale's Pharmacology Flash Cards

 

Description:

Organized in conjunction with Rang and Dale’s Pharmacology 9^th edition, Rang & Dale's Pharmacology Flashcards helps you review what you learn in class and reinforce essential information. One side of each flashcard features a diagram of the pathophysiological processes including the drug class at the top of the card. The back of the card details essential information for that drug class including actions, mechanism of action, pharmacokinetic aspects, adverse effects, the names of related drugs and important aspects of clinical use.

Completely updated with the latest knowledge in pharmacology and clinical use.

New chapter on drugs used for eye and skin conditions, new coverage of clinical use of biopharmaceuticals in a wide range of conditions, and a concise explanation of the rapidly growing impact of pharmacogenetics.

Clinical correlations help you apply information to real-life situations.

Compact and efficient size make it easy to carry selected cards with you and study on the go.

A perfect study aid and complement to Rang & Dale’s Pharmacology, 9th Edition–—ideal for exam preparation.

 

Table of Contents:

 

Section I Cholinergic pharmacology

1.01 Muscarinics – Eye

1.02 Antimuscarinics – Eye

1.03 Antimuscarinics – Gastrointestinal

1.04 Antimuscarinics – Bladder

1.05 Neuromuscular Blocker

1.06 Neuromuscular Blocker

1.07 Peripheral Anticholinesterases

1.08 Nicotinic Partial Agonists

Section II Noradrenergic pharmacology

2.01 β2-Receptor Agonist

2.02 β1-Receptor Antagonist

2.03 α- and β-Receptor Agonists

2.04 α1-Receptor Antagonist

2.05 β1-Receptor Agonist

2.06 α1-Receptor Agonist

2.07 Drugs That Release Noradrenaline

2.08 Selective β3-Adrenoceptor Agonist

2.09 α2-Agonist Prodrug

2.10 DOPA Decarboxylase Inhibitor

Section III Inflammation and anti-inflammatory drugs

3.01 NSAIDs

3.02 NSAIDs

3.03 NSAIDs

3.04 COX-2 Inhibitors

3.05 DMARDs

3.06 DMARDs

3.07 DMARDs

3.08 Uricosuric Agents

3.09 Antigout: Colchicine

Notes

Section IV Drugs affecting the immune response

4.01 Calcineurin Inhibitors

4.02 Antiproliferative Immunosuppressant

4.03 Antiproliferative Immunosuppressant

4.04 Antiproliferative Antibiotic

4.05 Glucocorticoids

4.06 TNF Inhibitors

4.07 Antibodies Against CD20

4.08 Monoclonal Antibodies (non-CD20)

4.09 Interleukin Inhibitors

4.10 JAK

4.11 Non-Sedating Antihistamines

4.12 Sedating Antihistamine

4.13 Drugs Affecting the Immune Response

Section V Antidysrhythmic drugs

5.01 Class Ia Antidysrhythmic

5.02 Class Ic Antidysrhythmic

5.03 Class II Antidysrhythmic

5.04 Class III Antidysrhythmic

5.05 Class IV Antidysrhythmic

5.06 Adenosine Receptor Agonists

5.07 Cardiac Glycoside

Section IV The vascular system

6.01 ACE Inhibitors

6.02 Angiotensin Antagonists

6.03 Calcium Channel Blockers

6.04 Potassium Channel Activator

6.05 Hydralazine

6.06 Endothelin Antagonist

Section VII The heart

7.01 Nitrates

7.02 Ivabradine

7.03 Ranolazine

Section VIII Drugs for eye and skin conditions

8.01 Glaucoma Eyedrops

Notes

8.02 VEGF Inhibitors

Notes

8.03 Retinoids

8.04 Treatment of Psoriasis

Notes

8.05 Skin Parasites

Notes

Section IX Atherosclerosis and lipoprotein metabolism

9.01 HMG-CoA Reductase Inhibitors

9.02 Fibrates

9.03 PCSK9 Inhibitors

9.04 Cholesterol-Absorption Inhibitors

9.05 Cholesterol-Absorption Inhibitors

Section X Haemostasis and thrombosis

10.01 Irreversible COX-1 Inhibitor

10.02 Adenosine (P2Y12) Antagonists

10.03 GPIIb/IIIa Receptor Antagonists

10.04 Other Antiplatelets Drugs

10.05 Plasminogen Activators

10.06 Plasminogen Inhibitor

10.07 Anticoagulants

10.08 Anticoagulants

10.09 Anticoagulants

10.10 Direct Oral Anticoagulants

Section XI Haemopoietic system and treatment of anaemia

11.01 Haematinic Agents

11.02 Haematinic Agents

11.03 Haematinic Agents

11.04 Haemopoietic Growth Factors

11.05 Haemopoietic Growth Factors

Section XII Respiratory system

12.01 β2-Receptor Agonists

12.02 Xanthines

12.03 Leukotriene Antagonists

12.04 Inhaled Muscarinic Antagonists

12.05 Inhaled Glucocorticoids

12.06 Inhibitor of Mast Cells

12.07 Inhibition of Interleukin-5

12.08 Anti-Fibrotic Agents

Notes

Section XIII Kidney

13.01 Loop Diuretics

13.02 Thiazide Diuretics

13.03 Potassium-Sparing Diuretics

13.04 Osmotic Diuretic

Section XIV Gastrointestinal tract drugs

14.01 H2 Antagonist

14.02 Proton Pump Inhibitors

14.03 Mucosal Protectants

14.04 Antacids

14.05 Prostaglandin E Agonist

14.06 5-HT3 Antagonists – Antiemetics

14.07 Other Antiemetics

14.08 Osmotic Laxatives

14.09 Bulk Laxatives

14.10 Stimulant Laxatives

14.11 Faecal Softeners

14.12 Other Drugs for Constipation

14.13 Antidiarrhoeal Agent

14.14 Other Drugs That Reduce GI Motility

Section XV The control of blood glucose and drug treatment of diabetes mellitus

15.01 Insulin

15.02 Sulfonylureas

15.03 Biguanides

15.04 Meglitinides

15.05 Glucagon-Like Peptide-1 Agonists

15.06 Dipeptidyl Peptidase Inhibitors

15.07 SGLT-2 Inhibitors

15.08 α-Glucosidase Inhibitors

15.09 Glucagon

Section XVI The pituitary and the adrenal cortex

16.01 Hypothalamic Hormones

16.02 Hypothalamic Hormones

16.03 Anterior Pituitary Hormones

16.04 Posterior Pituitary Hormones

16.05 Mineralocorticoid

Section XVII The thyroid

17.01 Thyroid Hormone Suppression

17.02 Thyroid Hormone Replacement

Section XVIII Bone metabolism

18.01 Antiresorptive Drugs

18.02 Antiresorptive Drugs

18.03 Antiresorptive Drugs

18.04 Antiresorptive Drugs

18.05 Anabolic Agents

18.06 Vitamin D Preparations

Section XIX Reproductive system

19.01 Oestrogens and Anti-Oestrogens

19.02 Progestogens and Anti-Progestogens

19.03 Combined Oral Contraceptive Pill

19.04 Gonadotrophins

19.05 Uterine Stimulants

19.06 Uterine Stimulants

19.07 Uterine Stimulants

19.08 Oxytocin Antagonist

19.09 Male Sex Hormone

19.10 Anti-Androgens

19.11 Phosphodiesterase Type V Inhibitors

Section XX Neurodegenerative disorders

20.01 Drugs Used in Parkinson's Disease

20.02 Drugs Used in Parkinson's Disease

20.03 Drugs Used in Parkinson's Disease

20.04 Drugs Used in Parkinson's Disease

20.05 Drugs Used in Parkinson's Disease

20.06 Drugs Used in Parkinson's Disease

20.07 Drugs Used in Alzheimer's Disease

20.08 Drugs Used in Alzheimer's Disease

20.09 Drugs Used in Multiple Sclerosis

Notes

Section XXI General anaesthetics

21.01 Inhalational Agents

21.02 Inhalational Agents

21.03 Intravenous Anaesthesia

Section XXII Anxiolytics and hypnotic drugs

22.01 Benzodiazepines

22.02 Z-drugs

22.03 Partial Serotonin Agonist

22.04 Other Insomnia Drugs

Notes

Section XXIII Antipsychotic drugs

23.01 First-Generation Antipsychotics

23.02 First-Generation Antipsychotics

23.03 First-Generation Antipsychotics

23.04 Second-Generation Antipsychotics

23.05 Second-Generation Antipsychotics

23.06 Second-Generation Antipsychotics

23.07 Second-Generation Antipsychotics

23.08 Second-Generation Antipsychotics

Section XXIV Antidepressant drugs

24.01 Tricyclics

24.02 SSRIs

24.03 SNRIs

24.04 Noradrenaline Reuptake Inhibitor

24.05 Monoamine Oxidase Inhibitors

24.06 α-Adrenoceptor & 5-HT Receptor Antagonist

24.07 Dopamine Reuptake Inhibitor

24.08 Drugs for Bipolar Disorder

24.09 Drugs for Bipolar Disorder

Notes

Section XXV Antiepileptic drugs

25.01 Sodium Channel Inhibitors

25.02 T-Type Calcium Channel Blockers

25.03 Broad-Spectrum Antiepileptic

25.04 Benzodiazepines

25.05 Barbiturates

25.06 Broad-Spectrum Antiepileptic

25.07 Broad-Spectrum Antiepileptic

25.08 AMPA Receptor Blockers

25.09 Broad-Spectrum Antiepileptic

25.10 Other Anticonvulsants

Section XXVI Analgesic drugs

26.01 Opioid Drugs

26.02 Opioid Drugs

26.03 Opioid Drugs

26.04 Opioid Drugs

26.05 Drugs Used for Neuropathic Pain

26.06 Drugs Used for Neuropathic Pain

26.07 Drugs Used for Neuropathic Pain

26.08 Other Analgesic Drugs

Notes

Section XXVII Psychoactive drugs

27.01 Psychomotor Stimulants

27.02 Psychomotor Stimulants

27.03 Psychomotor Stimulants

27.04 CNS Depressants

27.05 Other Psychoactive Drugs

Notes

27.06 Major Psychedelic Drugs

Section XXVIII Local anaesthetics

28.01 Rapid-Onset LAs

28.02 Slow- and Medium-Onset LAs

28.03 Topical LA

Section XXIX Antibacterial drugs

29.01 Beta-Lactam Antibiotics

29.02 Beta-Lactam Antibiotics

29.03 Beta-Lactam Antibiotics

29.04 Blockers of Peptidoglycan Synthesis

29.05 Bacterial Protein Synthesis Blockers

29.06 Bacterial Protein Synthesis Blockers

29.07 Bacterial Protein Synthesis Blockers

29.08 Bacterial Protein Synthesis Blockers

29.09 Bacterial Protein Synthesis Blockers

29.10 Antibiotics Affecting Topoisomerase

29.11 Blockers of Folate Synthesis/Action

29.12 Other Antibacterial Drugs

Notes

29.13 Antimycobacterials for Tuberculosis

Notes

29.14 Antimycobacterials for Leprosy

Notes

Section XXX Antiviral drugs

30.01 Reverse Transcriptase Inhibitors

30.02 Reverse Transcriptase Inhibitors

30.03 Protease Inhibitors

30.04 DNA Polymerase Inhibitors

30.05 Neuraminidase Inhibitors

30.06 Biopharmaceutical Antivirals

Notes

30.07 Drugs Used in HIV

Notes

30.08 Drugs Used in Hepatitis

Notes

Section XXXI Antiprotozoal drugs

31.01 Blood Schizonticides – Malaria

31.02 Tissue Schizonticide – Malaria

31.03 Folate Inhibitors – Malaria

31.04 Artemisinin Derivatives – Malaria

31.05 Treatment of Amoebiasis

31.06 Other Antiprotozoal Drugs

Section XXXII Antifungal drugs

32.01 Antifungal Antibiotics

32.02 Synthetic Antifungal Drugs – Azoles

32.03 Other Antifungal Drugs

Section XXXIII Mebendazole

33.01 Anthelminthic Drugs

33.02 Anthelminthic Drugs

33.03 Anthelminthic Drugs

33.04 Anthelminthic Drugs

33.05 Anthelminthic Drugs

33.06 Anthelminthic Drugs

33.07 Anthelminthic Drugs

Section XXXIV Anticancer drugs

34.01 Alkylating Agents and Similar Drugs

34.02 Antimetabolites

34.03 Cytotoxic Antibiotics

34.04 Plant Derivatives

34.05 Hormones

34.06 Protein Kinase Inhibitors

34.07 Monoclonal Antibodies

34.08 Anticancer Drugs

Section XXXV General principles

35.01 Agonists and Antagonists

35.02 Affinity

35.03 Efficacy

35.04 Competitive Antagonism

Section XXXVI Genetic variation and personalized medicine

36.01 Drug Efficacy

36.02 Drug Safety

36.03 Pharmacokinetics

Section XXXVII Absorption and distribution of drugs

37.01 Lipid Solubility and Ionization

37.02 Routes of Drug Administration

37.03 Bioavailability

37.04 Measurement of Bioavailability

37.05 Non-Target Binding of Drugs

37.06 Volume of Distribution, Vd

Section XXXVIII Drug metabolism and excretion

38.01 Phase I and Phase II Metabolism

38.02 Cytochrome P450 System

38.03 P450 Induction and Inhibition

38.04 Renal Excretion of Drugs

38.05 Other Routes of Excretion

Section XXXIX Pharmacokinetics

39.01 First-Order Elimination

39.02 Zero-Order Elimination

39.03 Plasma Half-Life

39.04 Clearance

Drug Index

 

An aparitie	4 Feb. 2020
Autor	Yoon Kong Loke MB BS MRCP MD , Katharina Mattishent
Dimensiuni	16.6 x 8.2 x 11.1 cm
Editura	Elsevier
Format	cards
ISBN	9780702079054
Limba	Engleza
Nr pag	561